Extracellular vesicles outperform adipose derived-mesenchymal stromal cells in alleviating osteoarthritis chondrocyte inflammation in vitro when incorpo-rated into platelet-derived fibrin gel
Authors
enrico.ragni@grupposandonato.it
Keywords
Adipose, cartilage, orthobiologics, platelet rich plasma, extracellular vesiclesAbstract
Background: Orthobiologics are increasingly used in orthopedics, with platelet rich plasma (PRP) widely applied for its autologous origin and bioactive content. PRP fibrin gels allow local retention and sustained release but show limited ability to restore stable hyaline cartilage. Mesenchymal stromal cells (MSCs) and extracellular vesicles (EVs) contained in the secretome may stimulate hyaline cartilage formation and be combined with PRP gels, yet a direct comparison between cell- and EV-containing PRP gels is lacking.
Methods: PRP fibrin gels embedding adipose-derived stromal cells (ASCs) or ASC-derived EVs (ASC-EVs) were compared in vitro on osteoarthritic chondrocytes. A vesicle-equivalent design was used: gels containing 5 ×106 ASCs/ml PRP, releasing ~10 ×109 EVs in 48 h, were compared with gels incorporating the same EV dose. Gel properties and effects of the gel released particles in 48 hours were assessed on pathologic chondrocyte viability, stress and inflammatory/catabolic gene expression.
Results: ASC-EVs supplemented PRP gels allowed the generation of equivalent gel volumes from reduced plasma amounts. ASC-EVs release preserved chondrocyte viability and metabolic activity and induced a broader downregulation of OA-related inflammatory and catabolic genes. In contrast, ASC-supplemented gels induced cellular stress and showed weaker anti-inflammatory effects.
Conclusions: ASC-EVs based PRP gels elicited a more favorable and controlled biological response than cell-based formulations, despite representing only part of the ASC secretome. These results support EV-based PRP gels as a promising, more standardized alternative for cartilage repair, deserving further in vivo validation.
References
- Mavrogenis AF, Karampikas V, Zikopoulos A, Sioutis S, Mastrokalos D, Koulalis D, Scarlat MM, Hernigou P. Orthobiologics: a review. Int Orthop. 2023;47(7):1645-1662. doi: 10.1007/s00264-023-05803-z.
- Buontempo MG, Alhanshali L, Shapiro J, Lo Sicco K, Garshick MS. Platelet-Rich Plasma Applications, The Past 5 Years: A Review Article. EMJ Dermatol. 2023. doi: 10.33590/emjdermatol/10309838.
- Gupta A, Maffulli N. Platelet Lysate and Osteoarthritis of the Knee: A Review of Current Clinical Evidence. Pain Ther. 2024;13(6):1377-1386. doi: 10.1007/s40122-024-00661-y.
- Andia I, Atilano L, Maffulli N. Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211004336. doi: 10.1177/1759720X211004336
- Dülgeroglu TC, Sen B. A review of the role of platelet rich fibrin in healing and regenerative process and its use in orthopaedic surgery. Med J SDU. 2019;26(3):354-61. doi: 10.17343/sdutfd.451366.
- Filardo G, Kon E, Roffi A, Di Matteo B, Merli ML, Marcacci M. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg Sports Traumatol Arthrosc. 2015;23(9):2459-74. doi: 10.1007/s00167-013-2743-1.
- Papalia R, Diaz Balzani L, Torre G, Tirindelli MC, Nobile C, Maffulli N, Denaro V. Intraoperative application Platelet rich fibrin, postoperative injections of PRP or microfracture only for osteochondral lesions of the knee: a five-year retrospective evaluation. J Biol Regul Homeost Agents. 2016;30(4 Suppl 1):41-49.
- Bozhokin MS, Bozhkova SA, Sopova JV, Leonova EI, Shubniakov MI, Rubel AA, Simental-Mendía M. Perspectives for using platelet-rich plasma in the treatment of knee osteoarthritis: Can it be improved through modifications of the protocol? Chin J Traumatol. 2026;29(1):32-39. doi: 10.1016/j.cjtee.2024.12.004.
- Aletto C, Oliva F, Maffulli N. Knee intra-articular administration of stromal vascular fraction obtained from adipose tissue: A systematic review. J Clin Orthop Trauma. 2022;25:101773. doi: 10.1016/j.jcot.2022.101773.
- Pintore A, Notarfrancesco D, Zara A, Oliviero A, Migliorini F, Oliva F, Maffulli N. Intra-articular injection of bone marrow aspirate concentrate (BMAC) or adipose-derived stem cells (ADSCs) for knee os-teoarthritis: a prospective comparative clinical trial. J Orthop Surg Res. 2023;18(1):350. doi: 10.1186/s13018-023-03841-2.
- Copp G, Robb KP, Viswanathan S. Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol. 2023;20(6):626-650. doi: 10.1038/s41423-023-01020-1.
- Caplan AI. Mesenchymal Stem Cells: Time to Change the Name! Stem Cells Transl Med. 2017;6(6):1445-1451. doi: 10.1002/sctm.17-0051.
- Roszkowski S. Therapeutic potential of mesenchymal stem cell-derived exosomes for regenerative medicine applications. Clin Exp Med. 2024;24(1):46. doi: 10.1007/s10238-023-01282-z.
- Zubair M, Abouelnazar FA, Iqbal MA, Pan J, Zheng X, Chen T, Shen W, Yin J, Yan Y, Liu P, Mao F, Chu Y. Mesenchymal stem cell-derived exosomes as a plausible immunomodulatory therapeutic tool for inflammatory diseases. Front Cell Dev Biol. 2025;13:1563427. doi: 10.3389/fcell.2025.1563427.
- Wang X, Xu L, Wu Z, Lou L, Xia C, Miao H, Dai J, Fei W, Wang J. Exosomes of stem cells: a potential frontier in the treatment of osteoarthritis. Precis Clin Med. 2024;8(1):pbae032. doi: 10.1093/pcmedi/pbae032.
- Zhang S, Chuah SJ, Lai RC, Hui JHP, Lim SK, Toh WS. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials. 2018;156:16-27. doi: 10.1016/j.biomaterials.2017.11.028.
- Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48(12):3464-74. doi: 10.1002/art.11365.
- Toupet K, Maumus M, Luz-Crawford P, Lombardo E, Lopez-Belmonte J, van Lent P, Garin MI, van den Berg W, Dalemans W, Jorgensen C, Noël D. Survival and biodistribution of xenogenic adipose mesenchymal stem cells is not affected by the degree of inflammation in arthritis. PLoS One. 2015;10(1):e0114962. doi: 10.1371/journal.pone.0114962.
- Ozeki N, Muneta T, Koga H, Nakagawa Y, Mizuno M, Tsuji K, Mabuchi Y, Akazawa C, Kobayashi E, Matsumoto K, Futamura K, Saito T, Sekiya I. Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats. Osteoarthritis Cartilage. 2016;24(6):1061-70. doi: 10.1016/j.joca.2015.12.018.
- Yang T, Ma H, Li K, Xiang J, Qiu J, Ding Y, Wang C, Lai H, Hu X, Liu S, Lou C, Hong Z, Chen Z, He D. A microsphere loaded with chondrocyte-targeting exosomes continuously deliver miR-148a for osteoarthritis therapy. Mater Today Bio. 2025;33:101944. doi: 10.1016/j.mtbio.2025.101944.
- Yang Z, Deng Z, Gao W, Zhang W, Fan X, Su K, Liu Z. Research progress on exosomes from different sources in osteoarthritis and cartilage injury. J Orthop Surg Res. 2025;20(1):582. doi: 10.1186/s13018-025-06000-x.
- Cavallo C, Desando G, D'Alessandro M, Grigolo B, Roseti L. Recent Evidence for Orthobiologics Combined with Hydrogels for Joint Tissue Regeneration: Focus on Osteoarthritis. Gels. 2025;11(7):551. doi: 10.3390/gels11070551.
- Fu YJ, Jian J, Liu C, Yi YF, Ding YT, Wen J, Li YF, Guo QJ. Application of stem cell-derived exosomes in bone and joint diseases: Recent advances enabled by diverse carrier technologies. World J Stem Cells. 2025;17(11):113631. doi: 10.4252/wjsc.v17.i11.113631.
- Rathod AP, Rathod Y, Baitule R, Pundkar G, Saodekar H. Platelet rich plasma applications in orthopedics: A review of recent advances. World J Orthop. 2025;16(12):110377. doi: 10.5312/wjo.v16.i12.110377.
- Khandan-Nasab N, Torkamanzadeh B, Abbasi B, Mohajeri T, Oskuee RK, Sahebkar A. Application of Platelet-Rich Plasma-Based Scaffolds in Soft and Hard Tissue Regeneration. Tissue engineering. 2025. doi: 10.1089/ten.teb.2024.0285
- Jalowiec JM, D'Este M, Bara JJ, Denom J, Menzel U, Alini M, Verrier S, Herrmann M. An In Vitro Investigation of Platelet-Rich Plasma-Gel as a Cell and Growth Factor Delivery Vehicle for Tissue Engineering. Tissue Eng Part C Methods. 2016;22(1):49-58. doi: 10.1089/ten.TEC.2015.0223.
- Reksodiputro MH, Pratama G, Wiweko B, Kusumawardhani E, Rahayu D, Nauli R, Martin VJ, Sandora N. Incubation of platelet-rich fibrin matrix with mesenchymal stem cells improves matrix stiffness. International Journal of Applied Pharmaceutics. 2020;12(3):111–116. doi: 10.22159/ijap.2020.v12s3.39604.
- Ragni E, De Luca P, Landoni S, Valli F, Mortati L, Palombella S, Talò G, Moretti M, de Girolamo L. High efficiency protocol for platelet derived fibrin gel loaded with mesenchymal stromal cells extracellular vesicles. Regen Ther. 2024;26:442-457. doi: 10.1016/j.reth.2024.06.020.
- Jiang Y, Wei ZY, Song ZF, Yu M, Huang J, Qian HY. Platelet membrane-modified exosomes targeting plaques to activate autophagy in vascular smooth muscle cells for atherosclerotic therapy. Drug Deliv Transl Res. 2025;15(9):3098-3118. doi: 10.1007/s13346-025-01792-1.
- Haider KH. Handbook of Regenerative Medicine: Cell-Free Therapy Approach (1st ed.). CRC Press, 2025.
- Ragni E, Perucca Orfei C, Sinigaglia F, de Girolamo L. Joint Tissue Protective and Immune-Modulating miRNA Landscape of Mesenchymal Stromal Cell-Derived Extracellular Vesicles under Different Osteoarthritis-Mimicking Conditions. Pharmaceutics. 2022;14(7):1400. doi: 10.3390/pharmaceutics14071400.
- Ragni E, Palombella S, Lopa S, Talò G, Perucca Orfei C, De Luca P, Moretti M, de Girolamo L. Innovative Visualization and Quantification of Extracellular Vesicles Interaction with and Incorporation in Target Cells in 3D Microenvironments. Cells. 2020;9(5):1180. doi: 10.3390/cells9051180.
- Phelan MP, Reineks EZ, Berriochoa JP, Schold JD, Hustey FM, Chamberlin J, Kovach A. Impact of Use of Smaller Volume, Smaller Vacuum Blood Collection Tubes on Hemolysis in Emergency Department Blood Samples. Am J Clin Pathol. 2017;148(4):330-335. doi: 10.1093/ajcp/aqx082.
- WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy. Available at: https://www.ncbi.nlm.nih.gov/books/NBK138650/ Las access date: 31/01/2026.
- Gupta A, Maffulli N, Jain VK. Red Blood Cells in Platelet-Rich Plasma: Avoid If at All Possible. Biomedicines. 2023;11(9):2425. doi: 10.3390/biomedicines11092425.
- Ganguly K, McRury ID, Goodwin PM, Morgan RE, Auge WK 2nd. Native Chondrocyte Viability during Cartilage Lesion Progression: Normal to Surface Fibrillation. Cartilage. 2010;1(4):306-11. doi: 10.1177/1947603510373918.
- Olivos-Meza A, Brittberg M, Martínez-Nava G, Landa-Solis C. Suitable characteristics in the selection of human allogeneic chondrocytes donors to increase the number of viable cells for cartilage repair. Cell Tissue Bank. 2023;24(4):725-735. doi: 10.1007/s10561-023-10074-4.
- Trzyna A, Banas-Zabczyk A. Adipose-Derived Stem Cells Secretome and Its Potential Application in "Stem Cell-Free Therapy". Biomolecules. 2021;11(6):878. doi: 10.3390/biom11060878.
- Kakroodi FA, Khodadoust E, Alizadeh M, Hayaei Tehrani RS, Sarabi PA, Rahmanian M, Vosough M. Current challenges and future directions of ATMPs in regenerative medicine. Regen Ther. 2025;30:358-370. doi: 10.1016/j.reth.2025.06.017.
- Car E, Barbier L, Huys I, Simoens S, Vulto AG. Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergence. Expert Opin Biol Ther. 2025;25(6):649-668. doi: 10.1080/14712598.2025.2507832.
- Zhang L, Xiang J, Zhang F, Liu L, Hu C. MSCs can be a double-edged sword in tumorigenesis. Front Oncol. 2022;12:1047907. doi: 10.3389/fonc.2022.1047907.
- Ragni E. Extracellular Vesicles: Recent Advances and Perspectives. Front Biosci (Landmark Ed). 2025;30(6):36405. doi: 10.31083/FBL36405.
- Migliorini F, Torsiello E, La Padula G, Oliva F, Maffulli N. The Association Between Sex and Osteoarthritis in the Physically Active Population: A Systematic Review. Sports Med Arthrosc Rev. 2022;30(2):87-91. doi: 10.1097/JSA.0000000000000346